Figure 2.

Investigator‐assessed progression‐free survival in Japanese postmenopausal women with estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer receiving palbociclib plus letrozole (N = 42). A, Visceral vs non‐visceral metastases at baseline. B, Disease‐free interval (≤12 mo vs >12 mo from end of treatment vs de novo metastatic disease). C, Ki‐67‐positive cells ≤20% vs >20% at baseline. D, Dose reduction vs no dose reduction (at the March 4, 2016 cutoff). mPFS, median progression‐free survival; NE, not estimable; NR, not reached